An efficient injectable formulation with block copolymer micelles for hydrophobic antitumor candidate-pyridazinone derivatives

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 World Health Organization. Cancer (Media centre). www.who.int/mediacentre/factsheets/fs297/en/.
  Google Scholar
• 2 Nicola F, Peter S, Alberto C et al. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol. Ther. 138(3), 470–484 (2013).
  MedlineGoogle Scholar
• 3 David JA. The valley of death in anticancer drug development: a reassessment. Trends Pharmacol. Sci. 33(4), 173–180 (2012).
  MedlineGoogle Scholar
• 4 Akahane A, Katayama H, Mitsunaga T. Discovery of 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinebutanoic acid (FK 838): a novel non-xanthine adenosine A1 receptor antagonist with potent diuretic activity. J. Med. Chem. 42(5), 779–783 (1999).
  Medline CASGoogle Scholar
• 5 Meade EA, Wotrin LL, Drach JC, Townsend LB. Synthesis and antiproliferative and antiviral activity of carbohydrate-modified Pyrrolo[2,3-d]pyridazin-7-one nucleosides. J. Med. Chem. 40(5), 794–801 (1997).
  Medline CASGoogle Scholar
• 6 Refaat HM, Khalil OM, Kadry H. Synthesis and anti-inflammatory activity of certain piperazinylthienylpyridazine derivatives. Arch. Pharm. Res. 30(7), 803–811 (2007).
  Medline CASGoogle Scholar
• 7 Siddiqui AA, Mishra R, Shaharyar M. Synthesis and characterization of new types of halogenated and alkylated imidazolidineiminothiones and a comparative study of their antitumor, antibacterial, and antifungal activities. Eur. J. Med. Chem. 46(6), 2280–2289 (2011).
  MedlineGoogle Scholar
• 8 Osamu T, Frank MC. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3(3), 233–245 (2003).
  MedlineGoogle Scholar
• 9 Liu SC, Hitoshi Y. P27-Associated G1 arrest induced by hinokitiol in human malignant melanoma cells is mediated via down-regulation of pRb, Skp2 ubiquitin ligase, and impairment of cdk2 function. Cancer Lett. 286(2), 240–249 (2009).• Demonstrated the potential of pyridazinone derivatives in antitumor activity.
  Medline CASGoogle Scholar
• 10 Zhou SG, Liao HM, Chao H et al. Design, synthesis and structure activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents. Eur. J. Med. Chem. 83(18), 581–593 (2014).
  Medline CASGoogle Scholar
• 11 Csókás D, Zupkó I, Károlyi BI et al. Synthesis, spectroscopy, x-ray analysis and in vitro antiproliferative effect of ferrocenylmethylene-hydrazinylpyridazin- -3(2H)-ones and related ferroceno[d]pyridazin-1(2H)-ones. J. Organomet. Chem. 743(15), 130–138 (2013).
  CASGoogle Scholar
• 12 Taleb H, Al T. Design and synthesis of novel tetrahydro-2H-pyrano-[3,2- -c]pyridazin-3(6H)-one derivatives as potential anticancer agents. Eur. J. Med. Chem. 45(12), 5724–5731 (2010).
  MedlineGoogle Scholar
• 13 Ovais S, Javed K, Yaseen S et al. Synthesis, antiproliferative and anti-inflammatory activities of some novel 6-aryl-2-(p-(methanesulfonyl)phenyl)- -4,5-dihydropyridazi-3(2H)-ones. Eur. J. Med. Chem. 67, 352–358 (2013).
  Medline CASGoogle Scholar
• 14 Rathish IG, Javed K, Ahmad S et al. Synthesis and evaluation of anticancer activity of some novel 6-aryl-2-(p-sulfamylphenyl)-pyridazin-3(2H)-ones. Eur. J. Med. Chem. 49, 304–309 (2012).
  Medline CASGoogle Scholar
• 15 Nahren MM, Dhananjay B, Nanda G. Why pyridine containing pyrido[2,3-d]pyrimidin-7-ones selectively inhibit CDK4 than CDK2: insights from molecular dynamics simulation. J. Mol. Graphics Modeling 28, 695–706 (010).
  Google Scholar
• 16 AVENTIS CO. WO2004/046130 (2004).•• Data showed the antitumor activity of 6-(4-morpholino-3-[trifluoromethyl]phenyl)pyridazin-3(2H)-one (DZO) and its synthetic methods.
  Google Scholar
• 17 Hu YH, Lou LG, Lin SJ et al. US2013/0281426 (2013).
  Google Scholar
• 18 Wu Y, Zhu Y, Hai L, Li J, Yu YG, Liu WJ. CN201410018618.0 (2014).
  Google Scholar
• 19 Wu Y, Wang YQ, Hai L, Qi TL, Yu YG, Lei F. CN201210192036.5 (2012).
  Google Scholar
• 20 Carr C, Julia N, Wigmore T. The side effects of chemotherapeutic agents. Curr. Anaesth. Crit. Care 19(2), 70–79 (2008).
  Google Scholar
• 21 Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, Mcneil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 61(6), 428–437 (2009).
  Medline CASGoogle Scholar
• 22 Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44(1), 235–249 (2000).
  Medline CASGoogle Scholar
• 23 Le Garrec D, Gori S, Luo L, Lessard D et al. Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J. Control. Release 99(1), 83–101 (2004).
  Medline CASGoogle Scholar
• 24 Chiappetta DA, Sosnik A. Poly(ethylene oxide)-poly-(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. Eur. J. Pharm. Biopharm. 66(3), 303–317 (2007).
  Medline CASGoogle Scholar
• 25 Fuhrmann K, Jessica D, Schulz, Marc A, Gauthier, Jean-Christophe L. PEG nanocages as non-sheddable stabilizers for drug nanocrystals. ACS Nano 6(2), 1667–1676 (2012).•• Demonstrated the advantage of biodegrable nanomicelles on anticancer drug delivery.
  Medline CASGoogle Scholar
• 26 Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 3(1), 16–20 (2009).
  Medline CASGoogle Scholar
• 27 Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5, 161–171 (2005).
  Medline CASGoogle Scholar
• 28 Service RF. Nanotechnology takes aim at cancer. Science 310, 1132–1134 (2005).
  MedlineGoogle Scholar
• 29 Alexis F, Rhee JW, Richie JP et al. New frontiers in nanotechnology for cancer treatment. Urol. Oncol. Semin. Ori. Invest. 26(1), 74–85 (2008).
  Medline CASGoogle Scholar
• 30 Wang X, Yang L, Chen Z, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J. Clin. 58(2), 97–110 (2008).
  MedlineGoogle Scholar
• 31 Wang YJ, Chen LJ, Tan LW et al. PEG-PCL based micelle hydrogels as oral docetaxel delivery systems for breast cancer therapy. Biomaterials 35(25), 6972–6985 (2014).
  Medline CASGoogle Scholar
• 32 Wang C, Long CF, Xie CS et al. Two novel nanoscale preparations of micelle and thermosensitive hydrogel for docetaxel to treat malignant tumor. J. Biomed. Nanotechnol. 9(3), 357–366 (2013).
  Medline CASGoogle Scholar
• 33 Wang YJ, Wang C, Wang YJ, Luo F, Yan X, Qian ZY. Micelles of methoxy poly(ethylene glycol)-poly(ε-caprolactone) as a novel drug delivery vehicle for Tacrolimus. J. Biomed. Nanotechnol. 9(2), 147–157 (2013).
  Medline CASGoogle Scholar
• 34 Xue BX, Wang YJ, Tang XH et al. Biodegradable self-assembled MPEG-PCL micelles for hydrophobic oridonin delivery in vitro. J. Biomed. Nanotechnol. 8(1), 80–89 (2012).
  Medline CASGoogle Scholar
• 35 Gou ML, Men K, Shi HS et al. Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale 3, 1558–1567 (2011).
  Medline CASGoogle Scholar
• 36 Gong CY, Xie YM, Wu QJ et al. Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. Nanoscale 4, 6004–6017 (2012).
  Medline CASGoogle Scholar
• 37 Gou ML, Zheng XL, Ke M et al. Poly(ε-caprolactone)/poly(ethylene glycol)/poly(ε-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery. J. Phys. Chem. B 113(39), 12928–12933 (2009).
  Medline CASGoogle Scholar
• 38 Wang YJ, Wang C, Fu SZ et al. Preparation of tacrolimus loaded micelles based on poly(ε-caprolactone)–poly(ethylene glycol)–poly(ε-caprolactone). Int. J. Pharm. 407(1–2), 184–189 (2011).
  Medline CASGoogle Scholar
• 39 Gou ML, Zheng L, Peng XY et al. Poly(ε-caprolactone)–poly(ethylene glycol)–poly(ε-caprolactone) (PCL–PEG–PCL) nanoparticles for honokiol delivery in vitro. Int. J. Pharm. 375(1–2), 170–176 (2009).
  Medline CASGoogle Scholar
• 40 Mei L, Zhang ZP, Zhao LY, Huang LQ. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv. Drug Deliv. Rev. 65(6), 880–890 (2013).•• Demonstrated the method to synthesize methoxy poly(ethylene glycol)-poly(lactide) and how to prepare the drug-loaded micelles and evaluate them.
  Medline CASGoogle Scholar
• 41 Dong YC, Feng SS. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 25(14), 2843–2849 (2004).
  Medline CASGoogle Scholar
• 42 Zheng XL, Kan B, Gou M et al. Preparation of MPEG-PLA nanoparticle for honokiol delivery in vitro. Int. J. Pharm. 386(1–2), 262–267 (2010).• Demonstrated the prominent property of the polymetric micelles in antitumor drug delivery.
  Medline CASGoogle Scholar
• 43 Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr. Pharm. Des. 12(36), 4669–4684 (2006).
  Medline CASGoogle Scholar
• 44 Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65(1–2), 271–284 (2000).
  Medline CASGoogle Scholar
• 45 Takahashi, Taisuke, Maeda, Jun, Inagaki, Yusuke: WO 2014133056 A1 (2014).
  Google Scholar
• 46 Gou ML, Li XY, Dai M et al. A novel injectable local hydrophobic drug delivery system: biodegradable nanoparticles in thermo-sensitive hydrogel. Int. J. Pharm. 359(1–2), 228–233 (2008).
  Medline CASGoogle Scholar
• 47 Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50, 219–44 (1966).
  Medline CASGoogle Scholar
• 48 Zheng XL, Kan B, Gou ML et al. Preparation of MPEG–PLA nanoparticle for honokiol delivery in vitro. Int. J. Pharm. 386(1–2), 262–267 (2010).
  Medline CASGoogle Scholar